contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


intervaccs-distribution-partner-dechra-launches-strangvac-in-finland

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Intervacc is an animal health group that develops vaccines for animals. The company develops and sells vaccines against animal diseases based on its own technology platform with fused recombinant proteins. Sales are currently carried out through its own organization in the Nordic region and through its partner Dechra Pharmaceuticals in the rest of Europe. The company's headquarters are located in Hägersten.

Intervacc

Intervacc AB (publ) announces today that its distribution partner, Dechra Pharmaceuticals PLC ("Dechra"), will launch Strangvac in Finland and vaccine vials are expected to be available for ...

Intervacc AB (publ) announces today that its distribution partner, Dechra Pharmaceuticals PLC ("Dechra"), will launch Strangvac in Finland and vaccine vials are expected to be available for delivery shortly. This launch is the result of an extended collaboration between Intervacc and Dechra, where Dechra now has the right to sell Strangvac in Finland. This is a natural development given Dechra's long-standing presence and strong organization in Finland."Dechra has a long and successful history in Finland, and it was a natural step for us to give Dechra the opportunity to sell Strangvac in Finland. We look forward to reaching more veterinarians and horse owners with our vaccine Strangvac," says Jonas Sohlman, CEO of Intervacc."We are excited to add this innovative vaccine to our existing broad equine product range and believe this can become a game changer in the approach to strangles" says Marie Jakobsen, Equine Product Manager at Dechra Nordics.For more information please contact: &nbsp;Jonas Sohlman, CEOPhone: +46 (0)8 120 10 600E-mail: jonas.sohlman@intervacc.se&nbsp;The information was submitted for publication, through the agency of the contact person set out above on May 5, 2025 at 13.15 CET.About StrangvacStrangvac, a vaccine against equine strangles, is approved for sale and marketing in the EU, as well as in the United Kingdom, Iceland, Norway, and Liechtenstein. It has been launched in Sweden, Denmark, the United Kingdom, France, Germany, Belgium, the Netherlands, Austria, Ireland, Poland, and Italy.About Dechra Dechra Pharmaceuticals is the exclusive distribution partner of Intervacc for the Strangvac vaccine in Europe excluding the Nordic and Baltic countries. Dechra is a global specialist in veterinary pharmaceuticals and related products. Dechra has expertise in the development, manufacturing, marketing and sales of high-quality products exclusively for veterinarians worldwide.About Intervacc Intervacc AB (publ) is an animal health group that develops vaccines for animals. The company develops and sells vaccines against animal diseases based on the proprietary technology platform with fused recombinant proteins. The Intervacc share is listed on Nasdaq First North Growth Market.&nbsp;Contact information for Certified AdviserEminova Fondkommission ABE-mail: adviser@eminova.se, Phone: +46 (0)8 - 684 211 10<div></div>